Cooper Co (COO) AI Stock Analysis

• Market Cap: $16.40B
• Dividend Yield: N/A
• Average Volume (3M): 1.72M
• Price to Earnings (P/E): 44.6
• Beta (1Y): 0.70
• Revenue Growth: 5.06%
• EPS Growth: -4.47%
• Country: US
• Employees: 16,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.15
• Shares Outstanding: 195,978,030
• 10 Day Avg. Volume: 1,582,125
• 30 Day Avg. Volume: 1,717,590
• PEG Ratio: -8.16
• Price to Book (P/B): 1.70
• Price to Sales (P/S): 3.42
• P/FCF Ratio: 32.24
• Enterprise Value/Market Cap: 1.18
• Enterprise Value/Revenue: 4.72
• Enterprise Value/Gross Profit: 7.33
• Enterprise Value/Ebitda: 18.94
• 1Y Price Target: $90.33
• Price Target Upside: 7.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): 4.52
• Revenue Forecast (FY): $4.32B

• Rating: 68 Neutral
• Price Target: $86.00 ▲(2.78% Upside)
• Action: Downgraded Date: 02/04/26
• Date: Action: Downgraded 02/04/26

The score is driven primarily by solid financial fundamentals (strong margins and a de-levered balance sheet) and an upbeat earnings-call outlook with strengthened free-cash-flow targets and capital return. These positives are tempered by weak technical momentum and a high P/E valuation, with additional (but smaller) support from favorable financing and governance events.

Positive Factors

High gross margin

A sustained gross margin above 65% signals durable pricing power and efficient production. This margin buffer helps absorb input cost shocks and tariffs, supporting long-term operating cash flows and enabling reinvestment in R&D, product launches, and brand building across business cycles.

De-levered balance sheet

A near-zero debt-to-equity ratio materially reduces financial risk and interest burden, giving management flexibility to fund organic growth, opportunistic M&A, or share repurchases without refinancing pressure. It improves resilience to economic downturns and supports multi-year planning.

Strong cash generation & FCF targets

Elevated operating cash flow and a raised multi-year FCF target indicate sustainable cash conversion capacity. Predictable FCF underpins capital returns, debt reduction and funding for new product launches, increasing optionality and reducing reliance on external financing over the medium term.

Negative Factors

Gross margin pressure

Tariff-driven and mix-related margin compression is a structural risk if geopolitical or supply-chain cost shifts persist. Persistent input cost headwinds can erode profitability, require sustained price increases or cost restructuring, and narrow scope for reinvestment or margin improvement.

Exposure to China & fertility softness

Significant China weakness and muted fertility demand point to geographic and end-market concentration risk. Slower recovery or prolonged consumer pressure in APAC or fertility services can suppress organic growth for key segments, limiting top-line durability over the next several quarters.

Declining return metrics

Negative recent EPS growth and a marked drop in ROE suggest the company is generating lower returns on equity. Even with low leverage, deteriorating returns can indicate inefficiencies or margin erosion that, if unresolved, will constrain long-term shareholder value creation and capital allocation effectiveness.

Cooper Co Business Overview & Revenue Model

Company Description

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

How the Company Makes Money

Cooper Co generates revenue through multiple key streams, including direct sales of its consumer goods through retail channels, online marketplaces, and wholesale distribution. The company also engages in strategic partnerships with major retailers and e-commerce platforms, which provide significant exposure and increased sales volume. Additionally, Cooper Co invests in brand development and marketing initiatives to enhance product visibility and consumer loyalty, thereby driving repeat purchases. The company also explores licensing agreements for its products, allowing for additional revenue through royalties while expanding its market reach.

Cooper Co Financial Statement Overview

Summary

Strong overall financial health: solid gross margin (over 65%), consistent revenue growth, and a notably improved balance sheet with materially reduced leverage (debt-to-equity now 0.0). Offsetting this, profitability metrics show some pressure (lower net/EBIT/EBITDA margins) and cash conversion ratios flagged at 0.0, which warrants monitoring.

Income Statement

Cooper Co has demonstrated consistent revenue growth over the years, with a recent growth rate of 1.154% in the latest period. The gross profit margin remains strong at over 65%, indicating efficient cost management. However, the net profit margin has slightly decreased to 9.16% from the previous year's 10.07%, suggesting some pressure on net profitability. The EBIT and EBITDA margins have also seen a decline, which could be a concern if the trend continues.

Balance Sheet

The company's balance sheet is robust, with a significant reduction in total debt, leading to a current debt-to-equity ratio of 0.0, down from 0.319 in the previous year. This indicates a strong equity position and reduced financial risk. However, the return on equity has decreased to 0.0%, which may suggest inefficiencies in generating returns from shareholders' equity.

Cash Flow

Cooper Co's cash flow statement shows a healthy operating cash flow of $796.1 million, with a free cash flow growth rate of 5.293%. The free cash flow to net income ratio is currently at 0.0, indicating that the company is generating sufficient cash relative to its net income. However, the operating cash flow to net income ratio is also at 0.0, which could imply potential issues in converting net income into cash.

Breakdown	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Oct 2021
Income Statement
Total Revenue	4.09B	3.90B	3.59B	3.31B	2.92B
Gross Profit	2.48B	2.60B	2.36B	2.14B	1.96B
EBITDA	1.05B	1.07B	885.90M	878.70M	823.90M
Net Income	374.90M	392.30M	294.20M	385.80M	2.94B
Balance Sheet
Total Assets	12.39B	12.32B	11.66B	11.49B	9.61B
Cash, Cash Equivalents and Short-Term Investments	110.60M	107.60M	120.90M	138.20M	95.90M
Total Debt	2.78B	2.58B	2.57B	2.76B	1.48B
Total Liabilities	4.16B	4.23B	4.11B	4.32B	2.66B
Stockholders Equity	8.24B	8.08B	7.55B	7.17B	6.94B
Cash Flow
Free Cash Flow	433.70M	288.10M	215.00M	450.40M	524.20M
Operating Cash Flow	796.10M	709.30M	607.50M	692.40M	738.60M
Investing Cash Flow	-372.90M	-764.60M	-449.00M	-1.83B	-450.30M
Financing Cash Flow	-425.90M	39.20M	-173.90M	1.19B	-311.40M

Cooper Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 83.67
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Positive. The current price of 83.67 is above the 20-day moving average (MA) of 82.30, above the 50-day MA of 82.26, and above the 200-day MA of 74.84, indicating a bullish trend. The MACD of 0.66 indicates Negative momentum. The RSI at 56.08 is Neutral, neither overbought nor oversold. The STOCH value of 74.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COO.

Cooper Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATR	74 Outperform	$9.25B	24.43	15.28%	1.50%	2.50%	25.05%
WST	72 Outperform	$18.32B	37.45	16.85%	0.32%	4.90%	-0.26%
COO	68 Neutral	$16.40B	44.65	4.59%	―	5.06%	-4.47%
HOLX	66 Neutral	$16.82B	31.27	10.86%	―	1.74%	-25.29%
MASI	63 Neutral	$13.01B	―	-17.93%	―	-16.03%	-813.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	47 Neutral	$10.48B	-12.13	-13.75%	2.75%	-21.20%	-325.40%

Cooper Co Corporate Events

Cooper Co Amends Loan Facilities to Enhance Flexibility

On February 3, 2026, The Cooper Companies, Inc. amended its 2021 Term Loan Agreement by extending the maturity date of $950 million of its term loans to February 3, 2031 while leaving the $550 million balance unchanged, removing the credit spread adjustment, increasing the cap on incremental term loans to the greater of $1.365 billion and 100% of consolidated EBITDA, and allowing loan pricing to be based either on the company’s senior unsecured long-term debt ratings or its consolidated net indebtedness to consolidated EBITDA ratio. On the same date, the company and CooperVision International Limited executed an amendment to their 2024 Revolving Credit Agreement to align its terms with the revised 2021 loan facility, including removal of credit spread adjustments, a move that streamlines Cooper’s capital structure, provides greater flexibility for additional borrowing, and could enhance its long-term funding stability and financial planning capacity for stakeholders.

The most recent analyst rating on (COO) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on Cooper Co stock, see the COO Stock Forecast page.

Cooper Co strikes board-refresh pact with Browning West

On December 22, 2025, CooperCompanies entered into a cooperation agreement with investment firm Browning West, under which the company appointed veteran medical device executive Walter M. Rosebrough Jr. to its board and its Corporate Governance and Nominating Committee, effective January 3, 2026. The deal commits Cooper to supporting Rosebrough’s election at the 2026 annual meeting, conducting a Browning West–approved search for an additional independent director with medical technology experience by June 30, 2026, capping the board at ten members during the agreement term, and giving due consideration to naming Rosebrough board chair by the end of 2026, while Browning West agrees to standstill and voting commitments, including backing the company’s full slate in 2026. The move, announced in a December 23, 2025 press release, effectively aligns Cooper with an influential shareholder, brings in a director with a strong track record of value creation in the medical device sector, and signals further board refreshment aimed at strengthening governance and supporting long-term shareholder value.

The most recent analyst rating on (COO) stock is a Hold with a $88.00 price target. To see the full list of analyst forecasts on Cooper Co stock, see the COO Stock Forecast page.

Cooper Co Announces Leadership Change Amid Financial Growth

On December 4, 2025, CooperCompanies announced that Robert S. Weiss resigned as Chairman of the Board, effective January 2, 2026, with Colleen E. Jay appointed as his successor. The company also reported its financial results for the fiscal fourth quarter and full year ending October 31, 2025, showing a 5% increase in revenue to $4.1 billion and a 12% rise in non-GAAP EPS to $4.13, despite a 4% decline in GAAP EPS. The company aims to drive long-term shareholder value through growth, profitability, and strategic investments.

The most recent analyst rating on (COO) stock is a Buy with a $88.00 price target. To see the full list of analyst forecasts on Cooper Co stock, see the COO Stock Forecast page.